Biocon and Zentiva have celebrated the “first generic liraglutide approved in a major regulated/ICH market” after an endorsement from the UK’s MHRA.
Biocon Limited and Zentiva have celebrated receiving a frontrunning approval for generic liraglutide after the UK Medicines and Healthcare Products Regulatory Agency endorsed the partners’ 6mg/ml solution for injection in pre-filled pen.
The firms underlined that the approval represented the “first generic liraglutide approved in a major regulated/ICH [International Council for Harmonisation of Technical
Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.
Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.
Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.
With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.
